Orbotech Q3 net profit $11.1m. vs $9.4m.

Net income for the first nine months of 2005 rose to $31.2m. from $23m., diluted EPS rose to 94 cents from 70 cents and revenue rose to $283.5m. from $227.4m.

By YIGAL GRAYEFF
November 8, 2005 06:58

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

Orbotech's third-quarter net profit rose to $11.1m. from $9.4m. a year earlier, boosted by increased sales of its equipment for inspecting printed circuit boards and flat-panel displays. The Yavne-based company said on Monday that in the three months ending September 30 earnings per diluted share rose to 33 cents from 29 cents and revenues rose to $93.7m. from $82.7m. Analyst expectations for EPS ranged from 30 cents to 32 cents and ranged from $90.9m. and $93.1m. for revenue, as compiled by Thomson Financial Network. Net income for the first nine months of 2005 rose to $31.2m. from $23m., diluted EPS rose to 94 cents from 70 cents and revenue rose to $283.5m. from $227.4m. In morning trading on Nasdaq, shares rose 3.5% to $21.89



More about:NASDAQ

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS